SG10201912212XA - Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof - Google Patents
Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereofInfo
- Publication number
- SG10201912212XA SG10201912212XA SG10201912212XA SG10201912212XA SG10201912212XA SG 10201912212X A SG10201912212X A SG 10201912212XA SG 10201912212X A SG10201912212X A SG 10201912212XA SG 10201912212X A SG10201912212X A SG 10201912212XA SG 10201912212X A SG10201912212X A SG 10201912212XA
- Authority
- SG
- Singapore
- Prior art keywords
- prodrug
- pharmaceutical compositions
- compositions containing
- containing substituted
- substituted polycyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016157732 | 2016-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201912212XA true SG10201912212XA (en) | 2020-02-27 |
Family
ID=61020748
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912212XA SG10201912212XA (en) | 2016-08-10 | 2017-08-09 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
SG11201900869QA SG11201900869QA (en) | 2016-08-10 | 2017-08-09 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900869QA SG11201900869QA (en) | 2016-08-10 | 2017-08-09 | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Country Status (21)
Country | Link |
---|---|
US (3) | US10759814B2 (en) |
EP (1) | EP3498281A4 (en) |
JP (2) | JP6249434B1 (en) |
KR (3) | KR20190014086A (en) |
CN (1) | CN110494141A (en) |
AR (1) | AR109315A1 (en) |
AU (2) | AU2017310774B2 (en) |
BR (1) | BR112019001911A2 (en) |
CA (1) | CA3033180C (en) |
CL (2) | CL2019000325A1 (en) |
CR (1) | CR20190123A (en) |
IL (1) | IL264709B2 (en) |
MA (1) | MA45939A (en) |
MX (2) | MX2019001640A (en) |
PE (1) | PE20190662A1 (en) |
RU (1) | RU2727962C1 (en) |
SG (2) | SG10201912212XA (en) |
TW (2) | TWI663172B (en) |
UA (1) | UA125218C2 (en) |
WO (1) | WO2018030463A1 (en) |
ZA (2) | ZA201900935B (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113004304B (en) * | 2015-04-28 | 2022-03-18 | 盐野义制药株式会社 | Substituted polycyclic pyridone derivatives and prodrugs thereof |
MX2018006966A (en) * | 2015-12-15 | 2018-09-21 | Shionogi & Co | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug. |
EP3426656B1 (en) | 2016-03-08 | 2021-05-12 | Novartis AG | Tricyclic compounds useful to treat orthomyxovirus infections |
CA3027840A1 (en) | 2016-06-20 | 2017-12-28 | Shionogi & Co., Ltd. | Method for producing substituted polycyclic pyridone derivative and crystal of same |
BR112019001911A2 (en) * | 2016-08-10 | 2019-05-07 | Shionogi & Co., Ltd. | substituted polycyclic pyridone derivative and prodrug containing pharmaceutical composition thereof |
JOP20170169A1 (en) | 2016-08-29 | 2019-01-30 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
WO2019052565A1 (en) * | 2017-09-18 | 2019-03-21 | 广东东阳光药业有限公司 | Influenza virus replication inhibitor and use thereof |
AR113748A1 (en) * | 2017-10-06 | 2020-06-10 | Shionogi & Co | STEREOSELECTIVE PROCESS TO PREPARE SUBSTITUTE POLYCYCLIC PIRIDONE DERIVATIVES |
CN111303147A (en) * | 2018-12-12 | 2020-06-19 | 银杏树药业(苏州)有限公司 | Pyridone derivative, composition thereof and application of pyridone derivative as anti-influenza virus medicament |
CN110041327B (en) * | 2018-01-17 | 2022-01-21 | 江西彩石医药科技有限公司 | Pyridone derivative, composition thereof and application of pyridone derivative as anti-influenza virus medicament |
CN111848615B (en) * | 2018-01-17 | 2022-05-17 | 江西彩石医药科技有限公司 | Pyridone derivative and anti-influenza virus pharmaceutical composition containing same |
BR112020017121A2 (en) * | 2018-02-28 | 2020-12-22 | Novartis Ag | DERIVATIVES FROM 10- (DI (PHENYL) METHIL) -4-HYDROXY-8,9,9A-10-TETRA-HYDRO-7H-PYRROLEUM [1 ', 2': 4,5] PIRAZINO [1,2-B] PIRIDAZINE-3,5-DIONA AND COMPOUNTS RELATED AS INHIBITORS OF ORTHOMYXOVIRUS REPLICATION FOR TREATMENT OF INFLUENZA |
CN108440564B (en) * | 2018-04-11 | 2019-08-06 | 安帝康(无锡)生物科技有限公司 | Substituted polycyclic carbamoylpyridone derivative and its prodrug |
WO2019208540A1 (en) * | 2018-04-24 | 2019-10-31 | 塩野義製薬株式会社 | Solid formulation having excellent stability |
BR122022006356B1 (en) * | 2018-04-24 | 2022-10-04 | Shionogi & Co., Ltd | SOLID DOSAGE FORM |
CN109956956B (en) * | 2018-05-15 | 2020-07-07 | 广东东阳光药业有限公司 | Preparation method of polycyclic pyridone compound |
CN108558907B (en) * | 2018-06-01 | 2019-08-09 | 海化生命(厦门)科技有限公司 | A kind of preparation method of key intermediate 2 |
WO2020020267A1 (en) * | 2018-07-27 | 2020-01-30 | 深圳市塔吉瑞生物医药有限公司 | Substituted polycyclic pyridone compound and prodrug thereof |
CN110872247A (en) * | 2018-08-29 | 2020-03-10 | 上海复星星泰医药科技有限公司 | Xofluza sulfur-containing heterocyclic compound, intermediate thereof and preparation method |
WO2020058745A1 (en) * | 2018-09-18 | 2020-03-26 | Shionogi & Co., Ltd. | Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof |
CN111377944A (en) * | 2018-12-25 | 2020-07-07 | 广东东阳光药业有限公司 | Baloxavir marboxil crystal form and preparation method thereof |
EP3934758A1 (en) | 2019-03-05 | 2022-01-12 | Assia Chemical Industries Ltd | Solid state forms of baloxavir marboxil |
SG11202109050WA (en) | 2019-03-12 | 2021-09-29 | Shionogi & Co | Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a complication risk factor |
EP3714889A1 (en) | 2019-03-29 | 2020-09-30 | F. Hoffmann-La Roche AG | Baloxavir for the prevention of transmission of influenza virus |
WO2020205832A1 (en) * | 2019-04-01 | 2020-10-08 | Nikang Therapeutics, Inc. | Fused polycyclic pyridone compounds as influenza virus replication inhibitors |
CN111825699B (en) * | 2019-04-15 | 2023-02-21 | 上海复星星泰医药科技有限公司 | Sulfur-containing heterocyclic compounds and process for producing the same |
RU2720305C1 (en) * | 2019-05-07 | 2020-04-28 | Андрей Александрович Иващенко | Substituted 3,4,12,12a-tetrahydro-1h-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione, pharmaceutical composition, methods for production and use thereof |
CN111909174B (en) * | 2019-05-08 | 2022-01-21 | 江西彩石医药科技有限公司 | Crystal form of pyridone derivative, preparation method and application |
CN110105372B (en) * | 2019-06-05 | 2022-05-10 | 南京焕然生物科技有限公司 | Preparation method of R-7- (benzyloxy) -tetrahydro-1H-oxazine pyrido-triazine-6, 8-diketone |
BR112022000503A2 (en) * | 2019-07-11 | 2022-06-07 | Nanjing Zhegxiang Pharmaceuticals Co Ltd | Compounds Useful for Treating Influenza Virus Infections |
CA3146423A1 (en) * | 2019-08-13 | 2021-02-18 | Stefan De Buck | Improved dosage of baloxavir marboxil for pediatric patients |
CN112552315B (en) * | 2019-09-26 | 2023-05-23 | 北京澳合药物研究院有限公司 | Purification method of baluo Sha Weima wave ester and derivative thereof |
CN114258395A (en) * | 2019-09-27 | 2022-03-29 | 广东东阳光药业有限公司 | Crystal form of ester compound and preparation method thereof |
CN112707862B (en) * | 2019-10-24 | 2022-09-27 | 广东东阳光药业有限公司 | Preparation method of polycyclic pyridone compound |
CN115175913B (en) * | 2019-11-13 | 2023-11-28 | 南京知和医药科技有限公司 | Substituted bistricycles and pharmaceutical compositions and uses thereof |
WO2021129799A1 (en) * | 2019-12-27 | 2021-07-01 | 广东东阳光药业有限公司 | Influenza virus replication inhibitor and use thereof |
CN112898346B (en) * | 2020-01-23 | 2023-11-10 | 南京知和医药科技有限公司 | Water-soluble polycyclic compounds, pharmaceutical compositions and uses thereof |
CN112876510A (en) * | 2020-02-10 | 2021-06-01 | 石家庄迪斯凯威医药科技有限公司 | Phosphate polycyclic compound, and pharmaceutical composition and application thereof |
CN111647005A (en) * | 2020-06-15 | 2020-09-11 | 安徽皓元药业有限公司 | Barosavir new crystal form and preparation method thereof |
CN111875619B (en) * | 2020-07-30 | 2021-06-25 | 深圳市新阳唯康科技有限公司 | Crystal form of Barosavir ester and preparation method thereof |
CN111961064A (en) * | 2020-08-25 | 2020-11-20 | 石家庄龙泽制药股份有限公司 | Novel crystal form of Barosavir ester and preparation method and application thereof |
CN112409379B (en) * | 2020-09-28 | 2023-07-28 | 长沙晶易医药科技股份有限公司 | Deuterated dihydrodibenzothiazepine compound and pharmaceutical composition containing same |
CN112400801B (en) * | 2020-12-07 | 2022-07-22 | 天津医科大学第二医院 | Laryngeal precancerous lesion animal model and construction method and application thereof |
CN116829153A (en) * | 2021-05-10 | 2023-09-29 | 南京征祥医药有限公司 | Crystal forms and application of compound for treating influenza |
CN116284048B (en) * | 2023-05-18 | 2023-08-15 | 长沙晶易医药科技股份有限公司 | Compound and preparation method, pharmaceutical composition and application thereof |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1830312A (en) * | 1919-05-08 | 1931-11-03 | Westinghouse Lamp Co | Electric lamp |
GB2280435A (en) | 1993-07-29 | 1995-02-01 | Merck & Co Inc | Anti-viral agent |
US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
BR9607098A (en) * | 1995-02-27 | 1997-11-04 | Gilead Sciences Inc | New selective viral or bacterial neuraminide inhibitors |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
WO2006066414A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
KR20080064182A (en) | 2005-10-27 | 2008-07-08 | 시오노기세야쿠 가부시키가이샤 | Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase |
WO2009042502A1 (en) | 2007-09-27 | 2009-04-02 | Air Cruisers Company | Vessel escape slides and associated equipment |
TWI518084B (en) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | Process for pyrone and pyridone derivatives |
ES2671550T3 (en) | 2009-06-15 | 2018-06-07 | Shionogi & Co., Ltd. | Polycyclic substituted carbamoylpyridone derivative |
JP5766690B2 (en) | 2010-04-12 | 2015-08-19 | 塩野義製薬株式会社 | Pyridone derivatives having integrase inhibitory activity |
RS57490B1 (en) | 2010-09-24 | 2018-10-31 | Shionogi & Co | Substituted polycyclic carbamoyl pyridone derivative prodrug |
US8859290B2 (en) | 2011-07-22 | 2014-10-14 | Rutgers, The State University Of New Jersey | Inhibitors of influenza endonuclease activity and tools for their discovery |
US20130102600A1 (en) | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
US20130102601A1 (en) | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
EP2861232A1 (en) | 2012-05-23 | 2015-04-22 | Savira Pharmaceuticals GmbH | 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a]pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease |
WO2013174930A2 (en) | 2012-05-23 | 2013-11-28 | Savira Pharmaceuticals Gmbh | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
CA2879245A1 (en) | 2012-08-06 | 2014-02-13 | Savira Pharmaceuticals Gmbh | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
US9573938B2 (en) | 2012-09-11 | 2017-02-21 | Rutgers, The State University Of New Jersey | Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones |
US9701638B2 (en) | 2012-11-09 | 2017-07-11 | Rutgers, The State University Of New Jersey | Therapeutic hydroxyquinolones |
RU2015132977A (en) | 2013-01-08 | 2017-02-14 | Савира Фармасьютикалз Гмбх | NAFTIRIDINO DERIVATIVES AND THEIR APPLICATION IN TREATMENT, REDUCING THE INTENSITY OR PREVENTION OF VIRAL DISEASE |
MA38323B1 (en) | 2013-01-08 | 2018-05-31 | Hoffmann La Roche | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
MX2015008288A (en) | 2013-01-08 | 2016-06-02 | Savira Pharmaceuticals Gmbh | Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease. |
CN105722831B (en) | 2013-09-12 | 2019-08-06 | 艾丽奥斯生物制药有限公司 | Pyridazinone compound and application thereof |
ES2821394T3 (en) | 2013-09-12 | 2021-04-26 | Alios Biopharma Inc | 7,8-dihydro-3H-pyrazino [1,2-b] pyridazin-3,5 (6H) -dione compounds and uses thereof |
JP2017521424A (en) | 2014-07-07 | 2017-08-03 | ザヴィラ ファーマシューティカルズ ゲーエムベーハー | Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases |
CA2953867A1 (en) | 2014-07-07 | 2016-01-14 | F. Hoffmann-La Roche Ag | Pyridopyrazine compounds and their use in the treatment, amelioration or prevention of influenza |
JPWO2016084922A1 (en) * | 2014-11-28 | 2017-09-07 | 塩野義製薬株式会社 | 1,2,4-Triazine derivative and pharmaceutical composition thereof |
CN113004304B (en) * | 2015-04-28 | 2022-03-18 | 盐野义制药株式会社 | Substituted polycyclic pyridone derivatives and prodrugs thereof |
FI3290424T3 (en) | 2015-04-28 | 2024-02-26 | Shionogi & Co | Substituted polycyclic pyridone derivatives and prodrug thereof |
US20170081331A1 (en) | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease |
WO2017072341A1 (en) | 2015-10-30 | 2017-05-04 | F. Hoffmann-La Roche Ag | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
MX2018006966A (en) | 2015-12-15 | 2018-09-21 | Shionogi & Co | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug. |
WO2017109088A1 (en) | 2015-12-23 | 2017-06-29 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
JP6806413B2 (en) | 2016-02-03 | 2021-01-06 | 塩野義製薬株式会社 | Polycyclic pyridone derivatives and their prodrugs |
WO2017156194A1 (en) | 2016-03-08 | 2017-09-14 | The Regents Of The University Of California | Compositions and methods for inhibiting influenza rna polymerase pa endonuclease |
EP3426656B1 (en) | 2016-03-08 | 2021-05-12 | Novartis AG | Tricyclic compounds useful to treat orthomyxovirus infections |
PL416447A1 (en) | 2016-03-10 | 2017-09-11 | Międzynarodowy Instytut Biologii Molekularnej i Komórkowej w Warszawie | Inhibitor of influenza virus nuclease (polymerase complex) |
WO2017158147A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
WO2017158151A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
CA3027840A1 (en) | 2016-06-20 | 2017-12-28 | Shionogi & Co., Ltd. | Method for producing substituted polycyclic pyridone derivative and crystal of same |
WO2017223231A1 (en) | 2016-06-21 | 2017-12-28 | Alios Biopharma, Inc. | (s)-8-(benzhydryl )-6-isopropyl-3,5-dioxo- 5, 6,7,8,-tetrahydro-3h-pyrazino-[1,2-b]pyridazin-yl-isobutyrate antiviral agent for use in treating influenza |
BR112019001911A2 (en) * | 2016-08-10 | 2019-05-07 | Shionogi & Co., Ltd. | substituted polycyclic pyridone derivative and prodrug containing pharmaceutical composition thereof |
JOP20170169A1 (en) | 2016-08-29 | 2019-01-30 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
CN108440564B (en) | 2018-04-11 | 2019-08-06 | 安帝康(无锡)生物科技有限公司 | Substituted polycyclic carbamoylpyridone derivative and its prodrug |
-
2017
- 2017-08-09 BR BR112019001911-1A patent/BR112019001911A2/en unknown
- 2017-08-09 AR ARP170102235A patent/AR109315A1/en unknown
- 2017-08-09 US US16/323,580 patent/US10759814B2/en active Active
- 2017-08-09 MA MA045939A patent/MA45939A/en unknown
- 2017-08-09 UA UAA201901914A patent/UA125218C2/en unknown
- 2017-08-09 PE PE2019000351A patent/PE20190662A1/en unknown
- 2017-08-09 CN CN201780063164.0A patent/CN110494141A/en active Pending
- 2017-08-09 AU AU2017310774A patent/AU2017310774B2/en active Active
- 2017-08-09 SG SG10201912212XA patent/SG10201912212XA/en unknown
- 2017-08-09 CA CA3033180A patent/CA3033180C/en active Active
- 2017-08-09 JP JP2017545688A patent/JP6249434B1/en active Active
- 2017-08-09 SG SG11201900869QA patent/SG11201900869QA/en unknown
- 2017-08-09 WO PCT/JP2017/028923 patent/WO2018030463A1/en unknown
- 2017-08-09 RU RU2019104987A patent/RU2727962C1/en active
- 2017-08-09 KR KR1020197000492A patent/KR20190014086A/en active Search and Examination
- 2017-08-09 EP EP17839530.7A patent/EP3498281A4/en active Pending
- 2017-08-09 CR CR20190123A patent/CR20190123A/en unknown
- 2017-08-09 MX MX2019001640A patent/MX2019001640A/en unknown
- 2017-08-09 KR KR1020197000258A patent/KR20190007517A/en active Search and Examination
- 2017-08-09 KR KR1020197000494A patent/KR20190018469A/en not_active Application Discontinuation
- 2017-08-10 TW TW106127161A patent/TWI663172B/en active
- 2017-08-10 TW TW108115903A patent/TWI711621B/en active
- 2017-10-24 JP JP2017204957A patent/JP6267397B1/en active Active
-
2019
- 2019-02-07 IL IL264709A patent/IL264709B2/en unknown
- 2019-02-07 CL CL2019000325A patent/CL2019000325A1/en unknown
- 2019-02-08 MX MX2021010629A patent/MX2021010629A/en unknown
- 2019-02-13 ZA ZA2019/00935A patent/ZA201900935B/en unknown
- 2019-12-18 ZA ZA2019/08427A patent/ZA201908427B/en unknown
-
2020
- 2020-07-24 US US16/937,877 patent/US11306106B2/en active Active
- 2020-08-04 CL CL2020002032A patent/CL2020002032A1/en unknown
-
2022
- 2022-03-08 US US17/689,194 patent/US20220281890A1/en not_active Abandoned
-
2023
- 2023-04-17 AU AU2023202350A patent/AU2023202350A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201908427B (en) | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | |
HK1248673A1 (en) | Substituted polycyclic pyridone derivative and prodrug thereof | |
IL282584B (en) | Quinoline derivatives and pharmaceutical compositions containing them | |
HK1259145A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
IL258082B (en) | Bezimidazole derivatives and pharmaceutical compositions containing them | |
IL251441A0 (en) | Imidazo pyridine derivatives and pharmaceutical compositions containing them | |
IL287571A (en) | Stabilizing camptothecin pharmaceutical compositions | |
LT3290424T (en) | Substituted polycyclic pyridone derivatives and prodrug thereof | |
IL253520A0 (en) | Macrocyclic compounds their preparation and pharmaceutical compositions containing them | |
PL3412660T3 (en) | Sulfonamide derivative and pharmaceutical composition containing same | |
IL249803B (en) | Azepanyl derivatives and pharmaceutical compositions containing them | |
SG10202008700VA (en) | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF |